momentum/speculative - The 175% one-year return reflects speculative trading around pipeline catalysts rather than fundamental value…
Rising interest rates negatively impact valuation multiples for unprofitable biotech/specialty pharma companies as investors demand higher…
Watch on earnings: Egrifta SV quarterly net revenue and sequential growth trends, Total prescriptions (TRx) and new prescriptions (NRx) from IQVIA or Symphony Health data, Gross-to-net percentage and average net revenue per patient.
One Sentence Summary:
Theratechnologies: the story is balanced — egrifta sv prescription trends and net revenue per patient (pricing/reimbursement changes).
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.